EMBO Molecular Medicine (Sep 2019)

Nuclear receptor corepressor 1 represses cardiac hypertrophy

  • Chao Li,
  • Xue‐Nan Sun,
  • Bo‐Yan Chen,
  • Meng‐Ru Zeng,
  • Lin‐Juan Du,
  • Ting Liu,
  • Hui‐Hui Gu,
  • Yuan Liu,
  • Yu‐Lin Li,
  • Lu‐Jun Zhou,
  • Xiao‐Jun Zheng,
  • Yu‐Yao Zhang,
  • Wu‐Chang Zhang,
  • Yan Liu,
  • Chaoji Shi,
  • Shuai Shao,
  • Xue‐Rui Shi,
  • Yi Yi,
  • Xu Liu,
  • Jun Wang,
  • Johan Auwerx,
  • Zhao V Wang,
  • Feng Jia,
  • Ruo‐Gu Li,
  • Sheng‐Zhong Duan

DOI
https://doi.org/10.15252/emmm.201809127
Journal volume & issue
Vol. 11, no. 11
pp. 1 – 14

Abstract

Read online

Abstract The function of nuclear receptor corepressor 1 (NCoR1) in cardiomyocytes is unclear, and its physiological and pathological implications are unknown. Here, we found that cardiomyocyte‐specific NCoR1 knockout (CMNKO) mice manifested cardiac hypertrophy at baseline and had more severe cardiac hypertrophy and dysfunction after pressure overload. Knockdown of NCoR1 exacerbated whereas overexpression mitigated phenylephrine‐induced cardiomyocyte hypertrophy. Mechanistic studies revealed that myocyte enhancer factor 2a (MEF2a) and MEF2d mediated the effects of NCoR1 on cardiomyocyte hypertrophy. The receptor interaction domains (RIDs) of NCoR1 interacted with MEF2a to repress its transcriptional activity. Furthermore, NCoR1 formed a complex with MEF2a and class IIa histone deacetylases (HDACs) to suppress hypertrophy‐related genes. Finally, overexpression of RIDs of NCoR1 in the heart attenuated cardiac hypertrophy and dysfunction induced by pressure overload. In conclusion, NCoR1 cooperates with MEF2 and HDACs to repress cardiac hypertrophy. Targeting NCoR1 and the MEF2/HDACs complex may be an attractive therapeutic strategy to tackle pathological cardiac hypertrophy.

Keywords